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Abstract
Introduction: Breast cancer is a genetically and phenotypically complex disease. To understand the role of miRNAs
in this molecular complexity, we performed miRNA expression analysis in a cohort of molecularly well-characterized
human breast cancer cell lines to identify miRNAs associated with the most common molecular subtypes and the
most frequent genetic aberrations.
Methods: Using a microarray carrying LNA™ modified oligonucleotide capture probes), expression levels of 725
human miRNAs were measured in 51 breast cancer cell lines. Differential miRNA expression was explored by
unsupervised cluster analysis and was then associated with the molecular subtypes and genetic aberrations
commonly present in breast cancer.
Results: Unsupervised cluster analysis using the most variably expressed miRNAs divided the 51 breast cancer cell
lines into a major and a minor cluster predominantly mirroring the luminal and basal intrinsic subdivision of breast
cancer cell lines. One hundred and thirteen miRNAs were differentially expressed between these two main clusters.
Forty miRNAs were differentially expressed between basal-like and normal-like/claudin-low cell lines. Within the
luminal-group, 39 miRNAs were associated with ERBB2 overexpression and 24 with E-cadherin gene mutations,
which are frequent in this subtype of breast cancer cell lines. In contrast, 31 miRNAs were associated with
E-cadherin promoter hypermethylation, which, contrary to E-cadherin mutation, is exclusively observed in breast
cancer cell lines that are not of luminal origin. Thirty miRNAs were associated with p16INK4 status while only a few
miRNAs were associated with BRCA1, PIK3CA/PTEN and TP53 mutation status. Twelve miRNAs were associated with
DNA copy number variation of the respective locus.
Conclusion: Luminal-basal and epithelial-mesenchymal associated miRNAs determine the subdivision of miRNA
transcriptome of breast cancer cell lines. Specific sets of miRNAs were associated with ERBB2 overexpression,
p16INK4a or E-cadherin mutation or E-cadherin methylation status, which implies that these miRNAs may contribute
to the driver role of these genetic aberrations. Additionally, miRNAs, which are located in a genomic region
showing recurrent genetic aberrations, may themselves play a driver role in breast carcinogenesis or contribute to
a driver gene in their vicinity. In short, our study provides detailed molecular miRNA portraits of breast cancer cell
lines, which can be exploited for functional studies of clinically important miRNAs.
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Introduction
Numerous lines of evidence indicate that breast cancer
is genetically and epigenetically not just one disease but
a diverse group of diseases with diverse clinically rele-
vant biological and phenotypical features. Recent tech-
nological advances in molecular profiling have led to the
identification of an increasing number of molecular sub-
types in breast cancer, each with distinct co-regulated
and anti-regulated genes. However, the biology of these
molecular subtypes and their underlying genetic drivers
may be affected by numerous biological factors, includ-
ing miRNAs.
miRNAs are a class of small nonprotein-coding genes
that regulate the expression of genes post-transcription-
ally via sequence-specific interaction with the 3’ UTR of
target mRNAs, resulting in inhibition of translation and/
or mRNA degradation [1,2]. A large number of studies
have established that miRNAs play essential roles in bio-
logical processes, such as development [3,4], cell prolif-
eration [5], apoptosis [6], stress response, and
tumorigenesis [7,8]. Aberrant expression levels of miR-
NAs have been observed in many solid cancers includ-
ing breast cancer. In breast cancer, the expression levels
of several miRNAs are significantly different between
normal and cancerous tissues, between breast cancers of
different molecular subtypes [9-11] with a different
prognosis [12-14], and between breast cancers showing
different responses to endocrine therapy [15,16]. Despite
significant progress in the last few years on miRNA biol-
ogy, the exact biological functions and the genetic fac-
tors driving their expression have been revealed for only
a limited number of miRNAs in breast cancer.
Human breast cancer cell lines are excellent experi-
mental models and renewable resources to investigate
biological functions of clinically important miRNAs both
in in vitro cultured conditions and in vivo when raised
as xenografts [6,17-20]. Here, using microarrays we ana-
lyzed miRNA expression levels in 51 molecularly well-
characterized human breast cancer cell lines. We
explored the association of individual miRNA expression
levels with intrinsic subtypes and the most common
recurrent genetic aberrations. Through this analysis, we
provide a catalog of miRNAs in human breast cancer
cell lines, which can be used to understand underlying
biology of clinically relevant miRNAs and to reveal the
genetic factors that may be involved in their regulation.
Materials and methods
Breast cancer cell lines
The cohort of 51 human breast cancer cell lines used in
this study is listed in Table 1. The origin of the cell
lines has been described elsewhere [21]. Prior to expres-
sion profiling, all cell lines were established to be
genetically unique, monoclonal and of correct identity
by performing STR profiling using the PowerPlex® 16
system (Promega, Madison, WI, USA). The PowerPlex®
16 system included 15 STRs and one gender-discrimi-
nating locus (Penta E, D18S51, D21S11, TH01,
D3S1358, FGA, TPOX, D8S1179, vWA, Amelogenin,
Penta D, CSF1PO, D16S539, D7S820, D13S317, and
D5S818).
The method involved isolation of the genomic DNA
from each breast cancer cell line using the QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany) and 10 ng of
the isolated DNA was used as the input for the multiplex
PCR. The following PCR conditions were used: 95°C for
11 minutes, 96°C for 1 minute, 10×(94°C for 30 seconds,
60°C for 30 seconds, 70°C for 45 seconds), 22×(90°C for
30 seconds, 60°C for 30 seconds, 70°C for 45 seconds),
and then 60°C for 30 minutes. The PCR was carried out
using primers linked with fluorescent dyes (6-carboxy-
4’,5’-dichloro-2’,7’-dimethoxy-fluorescein, fluorescein, and
carboxy-tetramethylrhodamine). The labeled amplicons
were detected using the 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) and data
were analyzed using the Genemarker 1.91 software from
Softgenetics (State College, PA, USA).
The end result for each cell line was an electrophero-
gram with each STR allele represented as one or more
peaks of an appropriate fluorophore. The authenticity of
all cell lines, except SUM cell lines, were assessed by
comparing the generated STR profiles with the source
STR profiles present in the American Type Culture Col-
lection and the Deutsche Sammlung von Mikroorganis-
men und Zellkulturen. As no reference is available, the
STR profiles of the SUM cell lines were matched with
the profiles generated from the earliest passage of these
cell lines stored in the in-house culture collection.
For experiments, each cell line was cultured in tripli-
cate on collagen-coated petri dishes in RPMI 1640 med-
ium supplemented with 10% heat-inactivated fetal
bovine serum and antibiotic agents (100 μg/ml penicillin
G and 80 μg/m streptomycin). The petri dishes were
placed in a humidified atmosphere of 5% CO2 and 95%
air at 37°C until cultures were 70 to 80% confluent.
Ethical approval of our study was not necessary as our
experiment involved only in vitro propagated human
breast cancer cell lines.
Total RNA isolation
Total RNA from all samples was isolated using RNAzol-
B reagent (Campro Scientific BV, Veenendaal, the Neth-
erlands) according to the manufacturer’s manual. Briefly,
a biological sample was lysed in RNAzol-B reagent and
the lysate was separated into an aqueous phase and an
organic phase after the addition of chloroform. DNA
Riaz et al. Breast Cancer Research 2013, 15:R33
http://breast-cancer-research.com/content/15/2/R33
Page 2 of 17
Table 1 Molecular and biochemical characterization of 51 human breast cancer cell lines
Cell line Molecular classification Clinically relevant protein expression
Intrinsic subtypea ER PGR ERBB2 EGFR CK5 CK8-18 CK19 CK14
SUM185PE Luminal - - - - - + + -
MDA-MB-175VII Luminal + - - - - + + -
BT483 Luminal + - - - - + + -
T47D Luminal + + - + - + + -
MDA-MB-415 Luminal + + - - - + + -
ZR75-1 Luminal + + - - - + + -
MCF-7 Luminal + + - - - + ND -
SUM52PE Luminal + - - - - + ND -
UACC812 Luminal + + ++ - - + + -
MDA-MB-361 Luminal + + ++ - - + + -
ZR75-30 Luminal + - ++ - - + + -
SK-BR-5 Luminal - - ++ - - + + -
OCUB-F Luminal - - ++ - + + + -
MPE600 Luminal + - ++ - - + + -
MDA-MB-134VI Luminal + - - - - + + -
SUM44PE Luminal + + - - - + + -
CAMA-1 Luminal + - - - - + + -
BT474 Luminal + + ++ - - + + -
MDA-MB-330 Luminal-ERBB2+ + - ++ - - + + -
HCC1419 Luminal-ERBB2+ + - ++ - - + + -
HCC202 Luminal-ERBB2+ - - ++ - - + + -
SUM190PT Luminal-ERBB2+ - - ++ - - + + -
SUM225CWN Luminal-ERBB2+ - - ++ - - + + -
UACC893 Luminal-ERBB2+ - - ++ + - + + -
SK-BR-3 Luminal-ERBB2+ - - ++ - - + + -
EVSA-T Luminal-ERBB2+ - + ++ - - + + -
MDA-MB-453 Luminal-ERBB2+ - - ++ - - + + -
HCC1569 ER-negative-ERBB2+ - - ++ + - - - -
HCC1954 ER-negative-ERBB2+ - - ++ + + + - -
HCC1500 ER-negative-ERBB2+ + + - - - + + -
DU4475 Other - - - - + - - -
SUM229PE Basal-like - - - + + + + -
HCC1937 Basal-like - - - + + + - -
MDA-MB-468 Basal-like - - - + + + + -
HCC1806 Basal-like - - - + + + + +
HCC70 Basal-like - - - + + + + -
HCC1143 Basal-like - - - + + + + -
BT20 Basal-like - - - + + + + -
SUM149PT Basal-like - - - + + + + -
HCC1395 Basal-like - - - + + - - -
SK-BR-7 Normal-like/claudin-low - - - + - + - -
Hs578T Normal-like/claudin-low - - - + - - - -
MDA-MB-231 Normal-like/claudin-low - - - + - - - -
SUM1315M02 Normal-like/claudin-low - - - + - - - -
MDA-MB-436 Normal-like/claudin-low - - - + - - - -
BT549 Normal-like/claudin-low - - - + - - - -
MDA-MB-157 Normal-like/claudin-low - - - + - - - -
SUM159PT Normal-like/claudin-low - - - + - - - -
MDA-MB-435s Normal-like/claudin-low - - - - - - - -
SUM102PT Normal-like/claudin-low ND ND ND ND ND ND ND ND
HCC38 Normal-like/claudin-low ND ND ND ND ND ND ND -
CK, cytokeratin; ER, estrogen receptor; EGFR, epidermal growth factor receptor; PGR, progesterone receptor. aCell lines are classified based on expression of the
intrinsic gene set defined by Perou and Colleagues [23]. For protein expression: +, expression; ++, overexpression; -, no expression; ND, not determined. Other
subtype includes DU4475 since it is not classified to any subtype of breast cancer by the intrinsic gene set.
Riaz et al. Breast Cancer Research 2013, 15:R33
http://breast-cancer-research.com/content/15/2/R33
Page 3 of 17
and protein were subsequently removed by carefully
transferring the aqueous phase containing RNA to a
fresh Eppendorf tube. The RNA was obtained from the
aqueous phase by an isopropanol precipitation, washed
with ethanol and air dried for subsequent procedures.
The purity of the isolated RNA was checked using
NanoDrop® ND-1000 (Isogen Life Science, De Meern,
the Netherlands) ensuring spectrophotometric ratios
of A260 nm/A280 nm ~2 and A260 nm/A230 nm ≥ 2, and the
quality control checks were performed according to the
previously described methodology [22].
Gene expression profiling
Total RNA (200 ng) was reverse transcribed, copied into
double-strand cDNA and labeled to yield biotin-labeled
cRNA using the 3’ IVT express Kit (Affymetrix, Santa
Clara, CA, USA) according to the manufacturer’s
instructions. Biotin-labeled cRNA was subsequently
fragmented and loaded onto an Affymetrix GeneTitan
instrument. The hybridization cocktail was applied to
Human Genome HT_HG-U133_Plus_PM GeneChip 96-
well arrays. All steps including hybridization, washing
and scanning were carried out automatically inside the
instrument. The raw data (.CEL files) were normalized
by the RMA method using the default settings of the
Affymetrix Expression Console™ software and were
used for statistical analysis. The microarray data were
deposited in the Gene Expression Omnibus data reposi-
tory [GEO:GSE41313].
For subtype classification of the cell lines, Perou and
colleagues’ intrinsic gene set of 496 genes [23] were
matched to the Affymetrix probe sets using Unigene
cluster numbers. Some of the genes have multiple probe
sets present. To ensure analysis of only the informative
probe sets, the probe sets that did not vary across all
samples were removed, leaving the most variable ones
for analysis (66% of the probe sets). These genes were
then used to cluster the breast cancer cell lines. The
intrinsic molecular subtypes were assigned as follows:
luminal-type cell lines that exhibited higher expression
of ESR1, GATA3, TFF3, and FOXA1; ERBB2-positive
cell lines that showed higher expression of ERBB2,
GRB7, and STARD3; basal-like cell lines, which were
characterized by higher expression of KRT5, KRT17,
BST2, and FABP7; and normal-like/claudin-low cell
lines that did not show KRT5 and KRT17 expression
and have low expression of claudin 3, claudin 4, and
claudin 7 genes. The ERBB2-positive cell lines were
further designated as luminal-ERBB2-positive and estro-
gen receptor (ER)-negative/ERBB2-positive cell lines,
because the former in addition to ERBB2 overexpression
also show ESR1 gene expression on microarray while
the latter do not.
miRNA expression analysis
miRNA expression profiling was performed using
miRNA microarrays according to a previously published
method [24]. In brief, 1 μg total RNA was labeled with
Cy3 using the ULS aRNA labeling kit (Kreatech,
Amsterdam, the Netherlands). The LNA™ modified oligo-
nucleotide capture probe set (miRBase version 10.0, anno-
tation version 13; Exiqon, Vedbaek, Denmark) was spotted
in duplicate on Nexterion E glass slides in Nexterion Spot
buffer (Schott, Elmsford, NY, USA) using a Virtek Chip-
writer Pro (Bio-Rad, Hercules, CA, USA). The RNA sam-
ple with a labeling efficiency > 15 pmol Cy3/μg RNA was
used for hybridization in a salt-based hybridization buffer
(Ocimum Biosolutions, Hyderabad, India) overnight at 60°
C using a Tecan HS4800 pro hybridization station. Hybri-
dized slides were scanned in a Tecan LS Reloaded scanner.
Data were extracted using Imagene software (6.0 standard
edition; TCAN, Chapel Hill, NC, USA). The raw data were
normalized using quantile normalization and used for sta-
tistical analysis. The normalized expression data are pro-
vided in Table S1 in Additional file 1. To validate our
findings, subsets of the differentially expressed miRNAs
between two miRNA-driven clusters were quantified using
the Taqman Human MicroRNA Assay Set from Applied
Biosystems (Nieuwerkerk aan den IJssel, the Netherlands)
as described previously [12].
SNP arrays
Genomic DNA from all cell lines was extracted using the
QIAamp DNA Mini Kit (Qiagen). Genomic DNA (500
ng) was used as the starting material to capture genome-
wide chromosomal aberrations with the aid of the Affy-
metrix Genome-Wide Human SNP 6.0 array technology.
The steps were performed according to Affymetrix’s
recommended protocols. In summary, after digestion of
the genomic DNA using either restriction enzymes NspI
or StyI, adaptors were ligated to the obtained DNA frag-
ments. These fragments were subsequently amplified
using PCR, fragmented, end-labeled with biotin and
hybridized onto GeneChip SNP 6.0 arrays. After hybridi-
zation the arrays were washed and scanned to generate
the raw data (.CEL files) using the Affymetrix Genotyping
Console™ software. The chromosomal gains and losses
were calculated using SNP copy number variation (CNV)
on the same chromosome. The chromosomal regions
containing gains or losses were correlated with the
expression level of the miRNAs located on the same
genomic regions. The SNP data were deposited in the
GEO data repository [GEO:GSE41313].
Protein expression and mutational analysis
Protein expression data of ER, progesterone receptor,
ERBB2, epidermal growth factor receptor, and cytokeratin
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(CK) 5, CK8-18, CK19, and CK14 were used from pre-
viously published work [25], except for 10 HCC cell lines
that were characterized by immunohistochemistry using
the same protocols as described before [25]. Mutational
analysis of p16INK4a, BRCA1, E-cadherin, PIK3CA, and
PTEN and promoter hypermethylation analysis of E-cad-
herin were previously reported for all cell lines except for
HCC cell lines. These were separately analyzed according
to the previously published methods [25] (data presented
in Table S2 in Additional file 1).
Hierarchical clustering and statistical analyses
Hierarchical clustering analyses of significant miRNAs
were performed using Cluster 3 software [26] and the
expression patterns of miRNAs and mRNAs in the heat
maps were visualized using Treeview 1.1.6 R2. Average
linkage clustering was carried out on both samples and
mRNA and miRNA expression data, respectively, using
Pearson correlation as a distance measure. Differential
expression of miRNAs between two groups was deter-
mined using the univariate t test in BRB-array tools 3.7
developed by Dr. Richard Simon and the BRB-Array-
Tools Development Team). A permutation value of P <
0.05 was considered statistically significant and used to
select differentially expressed miRNAs for supervised
hierarchical cluster analysis. The associations between
continuous variables were tested using Spearman Rank
correlation (Rs values). The Kruskal-Wallis test was
used to evaluate differences among groups and P < 0.05
was considered statistically significant.
Results
Molecular features of human breast cancer cell lines
The 51 human breast cancer cell lines that were used in
this study are listed in Table 1, together with the protein
expression results of ER, progesterone receptor, ERBB2,
epidermal growth factor receptor and CK5, CK8-18,
CK19, and CK14. All cell lines were first profiled for
global mRNA expression using microarrays, and the cell
lines in Table 1 are grouped into molecular subtypes
based on the expression of the intrinsic genes originally
described by Perou and colleagues [23].
A Pearson correlation based on the top 10% of vari-
ably expressed genes classified the cell line cohort into
two obvious groups (Figure 1). The first major group
included 27 cell lines, of which 17 expressed ER protein.
All cell lines in this group showed higher expression of
luminal intrinsic genes as defined by Perou and collea-
gues [23]. We therefore defined this group of breast
cancer cell lines as the luminal-group (Figure 1, left
block). On the other hand, the second group included
23 breast cancer cell lines all of which were ER-negative
and showed a predominant expression of basal intrinsic
genes. We defined this group of breast cancer cell lines
as “theER-negative/basal-group (Figure 1, right block).
Moreover, according to classification using the intrinsic
gene expressions [23], the luminal-group included nine
ERBB2-overexpressing breast cancer cell lines, which
did not cluster as a separate group. This result is in line
with clustering of clinical specimens where the majority
of luminal, ERBB2-positive tumors cluster with the
luminal B tumors [27]. Within the ER-negative/basal-
group, the basal-like and normal-like/claudin-low cell
lines clustered distinctively into two subgroups (Figure 1).
The DU4475 cell line could not be assigned to any sub-
type using the intrinsic gene set and was therefore desig-
nated as “the other” subtype.
Notably, the entire luminal-group of 27 cell lines
expressed luminal cytokeratins (such as CK8/18 and
CK19). The basal-like cell lines within the ER-negative/
basal-group expressed basal and luminal cytokeratins
(CK5, CK19, CK8-18), whereas all normal-like/claudin-low
cell lines lacked the expression of these cytokeratins except
for SK-BR-7 that exhibited CK8-18 expression (Table 1).
Furthermore, except for MDA-MB-435s, the entire ER-
negative/basal-group of 23 cell lines also expressed epider-
mal growth factor receptor protein (Table 1), which is a
known marker for basal-type breast cancer.
miRNA expression profiling revealed two groups of
breast cancer cell lines
miRNA expression profiling was carried out using
microarrays containing LNA™ capture probe sets
against 725 human miRNAs. After filtering out miRNAs
that were undetectable in most of the cell lines (57%),
413 miRNAs remained and were selected for further
analysis. Unsupervised hierarchical clustering based on
the most variable 87 miRNAs (with standard deviation ≥
0.75) revealed two prominent cell line clusters: a minor
cluster that included 18 cell lines and a major cluster
that included 33 cell lines (Figure 2). Based on intrinsic
subtyping, 17 of 18 cell lines present in the minor clus-
ter belonged to either the basal-like or the normal-like/
claudin-low subtypes, and interestingly 16 of them were
deficient of ER, progesterone receptor and ERBB2 pro-
tein expression (triple-negative). The other two cell lines
(HCC38 and SUN102PT) remained undetermined for
protein analysis due to technical reasons. On the other
hand, 29 of 33 breast cancer cell lines present in the
major cluster were of the luminal-type, and all cell lines
except SUM185 exhibited either one of the hormone
receptor proteins or showed ERBB2 protein expression.
The DU4475 cell line, which was previously proposed to
have a stem cell-like phenotype due to activation of the
Wnt signaling pathway [25,28], clustered at the edge
of the major cluster. As a whole, similar to mRNA
expression, miRNA expression profiling discriminated
cell lines into two major subtypes of breast cancer.
Riaz et al. Breast Cancer Research 2013, 15:R33
http://breast-cancer-research.com/content/15/2/R33
Page 5 of 17
Among the 87 most-variable expressed miRNAs across
the entire panel, a group of 15 miRNAs (hsa-miR-130a,
hsa-miR-886-5p, hsa-miR-886-3p, hsa-miR-222, hsa-
miR-21*, hsa-miR-29a, hsa-miR-23a, hsa-miR-24, hsa-
miR-30a, hsa-miR-27a, hsa-miR-22, hsa-miR-532-3p,
hsa-miR-100, hsa-miR-125b, hsa-miR-221) was signifi-
cantly higher expressed in the minor cluster as opposed
to other miRNAs (Figure 2, top red box). Another group
of 17 miRNAs (hsa-miR-575, hsa-miR-155, hsa-miR-26b,
hsa-miR-200a, hsa-miR-200b, hsa-miR-141, hsa-miR-
200c, hsa-miR-190b, hsa-miR-492, hsa-miR-640, hsa-
miR-196a, hsa-miR-29c, hsa-miR-93, hsa-miR-193a-3p,
hsa-miR-191, hsa-miR-26a, hsa-miR-182) showed signifi-
cantly higher expression in the major cluster compared
with the other miRNAs (fold change ≥ 1.5) (Figure 2,
bottom red box).
To confirm the validity of miRNA array data, we had
previously measured miRNA expression levels by real-
time RT-PCR in our laboratory available from 20 miR-
NAs differentially expressed between the major cluster
Figure 1 Molecular subtyping of 51 human breast cancer cell lines. Pearson correlation plot based on global mRNA expression of the top
10% variable genes. Breast cancer cell lines are depicted according to their overall similarity in gene expression. Yellow and blue, high and low
overall similarity of samples in mRNA expression, respectively. Two main groups of 27 and 23 cell lines were apparent. Color codes for breast
cancer subtypes based on intrinsic gene set: green, luminal-type cell lines; brown, luminal ERBB2-positive cell lines; black, normal-like/claudin-low
cell lines; orange, basal-like cell lines; blue, estrogen receptor (ER)-negative/ERBB2-positive cell lines; pink, other subtype cell lines.
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Figure 2 Global miRNA expression analysis of 51 human breast cancer cell lines. Unsupervised clustering across the breast cancer cell lines
using the 87 most variably expressed miRNAs. Yellow and blue, high expression and low expression of the particular miRNA in the particular
sample, respectively. Cell lines in the dendrogram of the hierarchical clustering based on miRNA expression are coded according to their intrinsic
subtypes and depicted at the bottom of the figure (for color codes see Figure 1 caption). Red boxes enlist the groups of miRNAs that show the
most robust cluster-specific differential expression in the cell lines. miRNA hsa-miR-21 in the red box of minor cluster failed to reach our criteria
of fold change ≥ 1.5.
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and the minor cluster for four ER-positive cell lines and
four ER-negative cell lines. On average, the expression
levels of these 20 miRNAs in these eight cell lines mea-
sured on two different platforms showed a positive cor-
relation (Rs = 0.53 and Rs = 0.35 for miRNAs that were
positively and negatively associated with ER status,
respectively) (see Table S3 in Additional file 1). These
data indicate that the differential expression of these
miRNAs measured by the LNA™-based microarray in
most of the cases could be validated by an independent
technique.
As the miRNA-driven major and minor clusters
included ER-positive (18 of 33) and ER-negative (all) cell
lines, respectively, we determined whether differential
expression of miRNAs between the two clusters is dri-
ven by ER status of the cell lines. For this analysis, we
grouped cell lines into ER-positive and ER-negative
based on mRNA expression of ER and performed super-
vised cluster analysis on these groups. We identified 79
differentially expressed miRNAs between ER-positive
and ER-negative cell lines (P < 0.05) (see Figure S1 in
Additional file 2 and Table S4A in Additional file 1),
of which 54 miRNAs were common to the 113 miRNAs
that were differentially expressed between the two clus-
ters identified through unsupervised analysis (see Table
S5 in Additional file 1). Interestingly, however, 59 miR-
NAs were uniquely differentially expressed between the
two miRNA-driven clusters whereas 25 miRNAs were
uniquely related to ER status of the cell lines (see Table
S6 in Additional file 1). To reveal whether ER-related
miRNAs in cell lines could be associated with the ER
status in clinical tumors, we used a publicly available
dataset from Cimino and colleagues comprising 77 pri-
mary breast tumors (53 ER-positive tumors and 24 ER-
negative tumors) [29] and determined differentially
expressed miRNAs between ER-positive and ER-negative
tumors. Among 37 miRNAs commonly detectable in
our data and in Cimino and colleagues’ dataset, the dif-
ferential expression of six miRNAs showed an overlap
between cell lines and primary tumors. Notably, however,
five of these six miRNAs (hsa-miR-141, hsa-miRNA-26a,
hsa-miR-29c, hsa-miR-148b, hsa-miR-193a-3p) showed
significantly higher expression in both ER-positive cell
lines and primary tumors, and one miRNA (hsa-miR-
532-3p) showed significantly lower expression in both
ER-positive cell lines and ER-positive tumors (see Table
S4B in Additional file 1).
miRNA expression of cell lines associated with molecular
intrinsic subtypes of breast cancer
We next aimed to identify miRNAs that are differen-
tially expressed between the intrinsic subtypes of breast
cancer. As expected, we observed a substantial overlap
of differentially expressed miRNAs between ER-positive
and ER-negative cell lines and the luminal-group and
ER-negative/basal-group of cell lines (see Figure S1 in
Additional file 2 and Tables S4A and S7 in Additional
file 1). To identify additional miRNAs that are related to
intrinsic subtypes but to avoid the confounding effect of
ER, we compared cell lines with and without ERBB2
overexpression within the luminal-group. Likewise we
compared the intrinsic basal-like cell lines with normal-
like/claudin-low cell lines within the ER-negative/basal-
group. These comparisons revealed 39 differentially
expressed miRNAs in luminal cell lines with or without
overexpressed ERBB2; 40 miRNAs were found differen-
tially expressed between basal-like and normal-like/clau-
din-low cell lines (P < 0.05) (Figure 3A, B; see Tables S8
and S9 in Additional file 1).
The top most highly expressed miRNAs in ERBB2 over-
expressing cell lines included hsa-let-7b, hsa-miR-640,
hsa-miR-200c, hsa-miR-378, hsa-miR-141, hsa-miR-196a,
hsa-miR-29c, and hsa-miR-18a*, whereas hsa-miR-501-5p,
hsa-miR-202, hsa-miR-760, and hsa-miR-626 were more
highly expressed in luminal cell lines lacking ERBB2 over-
expression (fold change ≥ 1.5) (see Table S8 in Additional
file 1). Similarly, the most highly expressed miRNAs in
normal-like/claudin-low cell lines were hsa-miR-22, hsa-
miR-532-3p, hsa-miR-125b, hsa-miR-501-5p, and hsa-
miR-155*, whereas in basal-like cell lines miRNAs of the
miR-200 family (hsa-miR-492, hsa-miR-26b, hsa-miR-617,
hsa-miR-155) were highly expressed (fold change ≥ 2) (see
Table S9 in Additional file 1). Notably, hsa-miR-155*
and hsa-miR-155, which derived from the same precur-
sor, showed an opposing expression pattern in basal-like
compared with normal-like/claudin-low breast cancer
cell lines.
Differential expression of miRNAs and E-cadherin loss in
breast cancer cell lines
E-cadherin elicits a growth suppressive effect in mam-
mary epithelial cells and its expression is frequently lost
in human breast tumors [30]. Loss of E-cadherin expres-
sion occurs either by gene mutation or by gene promo-
ter hypermethylation. In this cohort of cell lines and in
clinical specimens, E-cadherin is preferentially mutated
in luminal/ER-positive cell lines while it is frequently
inactivated by promoter hypermethylation in basal/ER-
negative cell lines [21]. To determine whether loss of E-
cadherin expression in human breast cancer cell lines is
associated with differential expression of miRNAs, we
compared 10 E-cadherin mutant cell lines with 17 wild-
type cell lines within the luminal-group of cell lines
(Figure 4A) and compared nine E-cadherin promoter
hypermethylated cell lines with eight nonmethylated cell
lines within the ER-negative/basal-group (Figure 4B).
Our comparison revealed signatures of 24 and 31 differ-
entially expressed miRNAs associated with E-cadherin
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mutant and wild type cell lines and with cell lines hav-
ing E-cadherin promoter hypermethylation or not,
respectively (P < 0.05) (Figure 4A, B; in see Tables S10
and S11 in Additional file 1). Interestingly, both E-cad-
herin signatures had no miRNAs in common showing
similar behavior.
Association of miRNAs expression with common genetic
aberrations (p16INK4a, TP53, BRCA1, PIK3CA, PTEN)
The BRCA1, p16INK4a, TP53, and PTEN genes play a
growth suppressive role in mammary epithelial cells and
are frequently inactivated in human breast tumor tissue.
PIK3CA is also frequently mutated in breast cancer but
has an oncogenic role. To reveal differentially expressed
miRNAs associated with these mutations, we performed
supervised analyses between mutant and wild-type cell
lines for these genes. To avoid the confounding effects
of ER, we performed these analyses only in ER-positive
or ER-negative cell lines.
In our cohort, 13 cell lines had lost the p16INK4a locus,
of which the majority are ER-negative. The comparison
revealed that 30 miRNAs were differentially expressed
between nine p16INK4a mutant cell lines and seven wild-
type cell lines in the ER-negative/basal-group (Figure 5;
see Table S12 in Additional file 1). The most highly
expressed miRNAs in p16INK4a mutant cell lines were
hsa-miR-29a and hsa-miR-100 (fold change ≥ 2). Nota-
bly, the p16INK4a miRNA signature in the ER-negative/
basal-group of cell lines appeared to be pronounced,
and when used for clustering could almost completely
separate the cell lines mutant for the p16INK4agene from
those that were wild-type. One should, however, empha-
size that the tumor suppressor genes p16INK4a and
p14ARF are co-localized and are often simultaneously
Figure 3 Molecular subtype-specific differential expression of miRNAs. Differentially expressed miRNAs (A) between luminal-type and
luminal ERBB2-positive breast cancer cell lines within the mRNA-derived luminal-group (see Figure 1), and (B) between basal-like and normal-
like/claudin-low breast cancer cell lines within the mRNA-derived estrogen receptor-negative/basal-group. Yellow and blue, high and low overall
similarity of samples in miRNA expression, respectively.
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lost amongst cell lines. We therefore cannot determine
which of these genes might drive the differential expres-
sion of these miRNAs.
Furthermore, the current cohort of breast cancer cell
lines contained 15 PIK3CA mutant cell lines (four ER-
negative, eleven ER-positive) and eight PTEN mutant
cell lines (four ER-negative, four ER-positive). Both
PIK3CA and PTEN are components of the PI3K signal-
ing pathway and mutated mutually exclusively in clinical
specimens [31] and also in this cohort of cell lines [32].
Separate analyses between PIK3CA or PTEN mutant
versus wild-type cell lines for these genes did not yield a
considerable number of differentially expressed miRNAs.
We therefore combined all cell lines harboring muta-
tions either in PIK3CA or PTEN and compared them
with wild-type cell lines. As PIK3CA/PTEN mutations
are present in both the luminal-group and the ER-nega-
tive/basal-group of cell lines, we therefore performed
multiple analyses. First, we analyzed all cell lines and
found 49 miRNAs, which were differentially expressed
between mutant and wild-type cell lines (see Figure S2A
in Additional file 2 and Table S13 in Additional file 1).
With successive analyses, we found eight and 42 differ-
entially expressed miRNAs among the ER-negative/
basal-group and the luminal group, respectively (see Fig-
ure S2A in Additional file 2 and Tables S14 and S15 in
Additional file 1).
With respect to BRCA1, which is mutated in four of
the ER-negative cell lines, we identified 13 miRNAs
being differentially expressed between four mutant cell
lines and 12 wild-type breast cancer cell lines (see Fig-
ure S2B in Additional file 2 and Table S16in Additional
file 1). The two most highly expressed miRNAs in
BRCA1 mutant cell lines were hsa-miR-29b and hsa-
miR-891b (fold change ≥ 2). Finally, we analyzed differ-
entially expressed miRNAs between TP53 mutant cell
Figure 4 Differential expression of miRNAs with respect to E-cadherin status. Differentially expressed miRNAs (A) between E-cadherin
mutant and wild-type breast cancer cell lines in the luminal-group, and (B) between E-cadherin promoter hypermethylated and wild-type breast
cancer cell lines in the estrogen receptor-negative/basal group. Cell lines HCC1806, SK-BR-7, SUM102PT, SUM149PT, and SUM229PE, which show
partial promoter hypermethylation, were not included in the analysis since we were not sure to which extent partial promoter methylation will
affect E-cadherin expression levels in these cell lines. Yellow and blue, high and low overall similarity of samples in miRNA expression,
respectively.
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Figure 5 Differentially expressed miRNAs between p16INK4a mutant and wild-type cell lines in the estrogen receptor-negative/basal-
group. The analysis was restricted to only the estrogen receptor (ER)-negative/basal-group of cell lines since the majority of p16INK4a mutant cell
lines were ER-negative. Yellow and blue, high and low overall similarity of samples in miRNA expression, respectively.
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lines (n = 39) and wild-type cell lines (n = 9) and found
18 to be associated with the TP53 mutation status (see
Figure S3 in Additional file 2 and Table S17 in Addi-
tional file 1). Important to note, however, is that the dif-
ferentially expressed miRNA signatures associated with
BRCA1, PIK3CA/PTEN, and TP53 mutations did not
strongly discriminate between mutant and wild-type cell
lines, and therefore their significance may be of limited
value.
miRNA genes show genomic aberrations in breast cancer
cell lines
Previous studies show that DNA CNVs in breast tumor
tissues can lead to differential expression of genes and
miRNAs [33-35]. To investigate this in our cohort of
breast cancer cell lines, we first determined the DNA
CNVs of the cell lines by performing whole-genome SNP
profiling. These CNVs were then correlated with the
expression levels of the 87 most variably expressed miR-
NAs in the cell lines. The correlation revealed 12 miRNAs,
which were significantly associated with DNA CNVs
(Kruskal-Wallis test, P < 0.05) (see Table S18 in Additional
file 1). The top four most significantly associated miRNAs
- hsa-miR-130a (11q12.1), hsa-miR-22 (17p13.1), hsa-miR-
93 (7q22.1) and hsa-miR-383 (8p22) - with DNA CNVs in
breast cancer cell lines are shown in Figure 6.
Discussion
Human breast cancer cell lines are renewable resources
that are extensively utilized as reliable workhorses to
explore biological functions of clinically relevant mole-
cules in breast cancer. Extensive molecular characteriza-
tion and gene mutation analysis by us and other
researchers have suggested that breast cancer cell lines
have retained significant molecular features that are com-
monly observed in clinical breast tumors [36,37]. This
suggestion prompted us to use 51 human breast cancer
cell lines as a discovery cohort to identify differentially
expressed miRNAs between known intrinsic subtypes of
breast cancer as well as those associated with common
genetic aberrations present in the cell lines.
In this study, we demonstrated that global miRNA
expression profiling can assign our cell line collection
into two clusters. These two clusters predominantly
mirror the ER-based dichotomy present in human breast
cancer cell lines, which may point to the fact that, like
mRNA, miRNA expression profiling allows the discrimi-
nation between ER-positive and ER-negative cell lines.
This suggests that a significant number of miRNAs may
be under the control of ER regulation. In line with this,
we observed a trend of finding ER binding sites closer
to the significantly differentially expressed miRNAs
between ER-positive and ER-negative cell lines than
nonsignificant miRNAs (see Table S19 in Additional file
1 and Figure S4 in Additional file 2). Interestingly, not
all miRNAs discriminating ER-positive and ER-negative
cell lines are associated with ER status and therefore the
division of the cell lines into two clusters may not be
purely dictated by the expression of ER-related miRNAs,
but these miRNAs are probably also related to luminal
versus basal cellular differentiation.
Our supervised analysis revealed a signature of 79 dif-
ferentially expressed miRNAs between ER-positive and
ER-negative cell lines. Six of these miRNAs were also
found similarly differentially expressed between ER-posi-
tive and ER-negative primary tumor specimens as they
were in cell lines [29] (see Table S4B in Additional file
1). This overlap may seem small but we have observed
discrepancies between miRNA profiling platforms
(unpublished observations), and our study used LNA™
technology-based microarrays to quantify miRNA
expression in the cell lines whereas Cimino and collea-
gues used Agilent microarrays to measure miRNAs in
tumors. Also not all miRNAs are present on both plat-
forms, which already explains one-half of the discrepan-
cies. Furthermore, tumor heterogeneity and stromal
contribution (such as connective tissues, blood vessels
and immune infiltrates) and a likely selection bias in the
cell lines - which are more ER-negative, mesenchymal,
and TP53 mutant than primary tumors - could explain
the observed discrepancies. A perfect correlation would
thus not have been anticipated. Reassuringly, however,
we found miRNAs previously reported to be ER-regu-
lated miRNAs, such as a cluster of hsa-miR-221/222
[12,38]. In line with this, we also found a significant
inverse correlation between the expression levels of
these ER-regulated miRNAs and mRNA expression
levels of their functionally validated target genes - for
instance, hsa-miR-221and hsa-miR-222 have been
shown to target the CDKN1B and ESR1genes (see Table
S20 in Additional file 1). Such miRNAs have been
shown to interact directly with ER and cause a phenoty-
pic shift from ER-positive to ER-negative tumor cells
[38]. Our miRNA analyses in this cohort of cell lines
therefore confirms previous findings but also revealed
new miRNAs (discussed below), which may have poten-
tially interesting biological roles in ER-driven cancer.
Among these potentially novel ER-related miRNAs,
four miRNAs (hsa-miR-26a, hsa-miR-92b, hsa-miR-191,
hsa-miR-492) appear to show consistently higher expres-
sion across all the ER-positive cell lines (fold change ≥
1.5), and as yet only hsa-miR-26a has been implicated in
breast carcinogenesis whereas hsa-miR-26a and hsa-
miR-92b have also been implicated in brain tumors
[39,40]. In breast cancer, high expression of the hsa-
miR-26a miRNA downregulates EZH2 and is therefore
related to a favorable outcome on tamoxifen in meta-
static breast cancer [41], and also interacts with CDK4
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and CENTG1 oncogenes and forms an integrated onco-
mir/oncogene DNA cluster, which promotes glioblas-
toma tumor growth via RB1, PI3K/AKT, and JNK
pathways [39]. On the other hand, hsa-miR-92b has
been found to be exclusively overexpressed in primary
brain tumors but serves as a biomarker to discriminate
brain primary cancer from metastasis [40]. The other
two miRNAs (hsa-miR-191, hsa-miR-492) have been
linked to hepatic cancer. The increased expression of
hsa-miR-191 stimulates proliferation in hepatocellular
carcinoma cell lines and its therapeutic targeting sup-
presses tumor masses in vivo [42]. The hsa-miR-492
miRNA has been shown to be processed from the kera-
tin 19 gene and upregulated in metastatic hepatoblas-
toma [43]. How these miRNAs play their biological
roles in the context of breast cancer remains unknown
and demands clinical and functional validation studies.
Another major contribution to the overall miRNA
profiling of this cell line cohort is the identification of a
signature of 42 differentially expressed miRNAs, which
discriminates between basal-like and normal-like/clau-
din-low breast cancer cell lines. These miRNAs together
with the ER-associated miRNAs are the major determi-
nants of the overall clustering of the cell lines. Impor-
tantly, this signature includes all four members of the
hsa-miR-200 family (hsa-miR-200a, hsa-miR-200b, hsa-
miR-200c, hsa-miR-141), hsa-miR-155, and hsa-miR-622
miRNAs. Several studies have implicated these miRNAs
to be involved in epithelial-mesenchymal transition
(EMT), to be related to the stem-cell-like phenotype,
and to be associated with a switch in paclitaxel respon-
siveness [44-47]. In breast cancer, these miRNAs are
known to regulate the EMT process by targeting the
ZEB family of the transcription factors through an active
Figure 6 Association of miRNA expression with genomic copy number variation in breast cancer cell lines. The top four most significant
miRNAs are represented (see Table S16 in Additional file 1 for a complete list). The Kruskal-Wallis test was used to reveal significant associations
of miRNAs with genome copy number (CN) variation. y axis, expression levels of miRNA; x axis, number of samples with CN loss/gain or neutral.
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negative feedback loop [48,49]. Importantly, the ZEB
family of transcription factors was reported to be a
repressor of E-cadherin expression in several epithelial
carcinomas including breast carcinoma.
Interestingly, we observed a significant inverse correla-
tion between the expression levels of all miRNAs of the
hsa-miR-200 family and the mRNA expression level of
the ZEB1 transcription factor, which is a well-known tar-
get of this miRNA family (see Table S20 in Additional
file 1). Additionally, our finding that the hsa-miR-200
cluster showed lower expression in normal-like/claudin-
low breast cancer cell lines fits with the fundamental lit-
erature that these miRNAs are indeed involved in EMT,
because the majority of the normal-like/claudin-low cell
lines lack E-cadherin protein expression, exhibit low clau-
din expression, and generally display EMT-like features
as well as the breast cancer stem cell phenotype
(CD44high/CD24low) [50-53]. Other known significant
miRNAs of this signature are hsa-miR-155 and hsa-miR-
622, which were also linked to enhanced tumorigenesis
in various cancer types besides breast cancer [54,55]. In
concordance with this, we recently found that the nor-
mal-like/claudin-low cell lines with low expression of
these EMT-related miRNAs show highly aggressive
growth characteristics in vivo when raised as xenografts
in nude mice (M Riaz and colleagues, unpublished data).
Importantly, this signature includes three previously
unknown miRNAs (hsa-miR-492, hsa-miR-26b, hsa-miR-
617; fold change ≥ 1.5) found to be associated with cell
lines frequently showing EMT-like characteristics.
We observed that the miRNA signatures associated
with E-cadherin mutation and promoter hypermethyla-
tion include distinct miRNAs. This may point to an
existence of unique biology at the miRNA level in
tumors that show E-cadherin inactivation due to gene
mutation rather than those that lose E-cadherin expres-
sion due to promoter hypermethylation. Important to
note is that E-cadherin promoter hypermethylated cell
lines include all normal-like/claudin-low cell lines, and
most EMT-related miRNAs were also associated with
E-cadherin promoter hypermethylation.
With respect to common genetic aberrations present in
breast cancer, our study reveals differentially expressed
miRNA signatures associated with commonly mutated
tumor suppressors and oncogenes. Most significantly, a
signature of 30 miRNAs associated with p16INK4a mutant
cell lines can strongly discriminate between mutant and
wild-type ER-negative cell lines. P16INK4a is a tumor sup-
pressor gene located on chromosomal band 9p21 that
has been frequently altered in many human cancers [56].
P16INK4a regulates cell cycle progression by targeting
CDK4/6 through the pRb signaling pathway. Interestingly,
this signature includes some miRNAs that are involved in
cell cycle regulation. For instance, hsa-miR-100, which is
highly expressed in the p16INK4a wild-type cell lines, tar-
gets the RBSP3 gene that in acute myeloid leukemia reg-
ulates the cell cycle through partial modulation of pRB/
E2F1 [57]. hsa-miR-34a has been reported as a suppres-
sor of cell proliferation and migration in colon cancer
[58] and its mechanism of growth inhibition also involves
cell cycle arrest followed by apoptosis [59]. Besides this,
we found a few miRNAs to be only associated with muta-
tion in BRCA1, TP53 and PIK3CA/PTEN; these observed
associations require further independent validation in
breast cancer specimens.
Our finding that the differential expression of miRNAs
is associated with ERBB2-overexpressing luminal-type cell
lines is also intriguing since the miRNAs showing ele-
vated expression in ERBB2-positive cell lines (fold change
≥ 1.5) are not located on the ERBB2 amplicon (17q12)
and thus may be regulated indirectly by genes in the
ERBB2 amplicon. It is also important to mention that a
majority of these miRNAs have already been implicated
in various types of epithelial carcinoma including breast
cancer [60-64]. One should, however, note that our study
is associative and does not necessarily reveal causality.
We therefore propose functional studies on these miR-
NAs to reveal more biological insights into their role
regarding ERBB2 overexpression in breast cancer.
Finally, we also identified 12 miRNAs to be associated
with CNVs in breast cancer cell lines (see Table S17 in
Additional file 1). The majority of these miRNAs (hsa-
miR-130a, hsa-miR-93, hsa-miR-383, hsa-miR29c, hsa-
miR-382, hsa-miR-31) were already found to be located
in regions that exhibited DNA copy number abnormal-
ities in breast cancer tumors [65]. Importantly, this
repertoire of miRNAs includes hsa-miR-22 previously
shown to be regulated by ER [66] and we provide evi-
dence that it can also be regulated by the loss of the
locus containing this miRNA. Six miRNAs of this reper-
toire are located in the genomic regions containing
known protein coding genes. All miRNAs of this reper-
toire have also been implicated in various cancers but a
thorough validation of these miRNAs with respect to
DNA copy number changes in clinical specimen is
imperative.
Conclusion
In summary, our analyses show that the dichotomy in
breast cancer cell lines is, in line with the general con-
sensus in the field, related to ER status. However, part
of this dichotomy may be related to ER-independent
luminal versus basal differentiation status of cell lines.
Secondly, another prominent dichotomy observed
among breast cancer cell lines discriminating basal-like
cell lines from normal-like/claudin-low cell lines
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involves miRNAs related to EMT and/or stemness.
Furthermore, we reveal sets of miRNAs associated
with genes frequently amplified (ERBB2) or mutated
(p16INK4a, PIK3CA and/or PTEN, E-cadherin, BRCA1) in
breast cancer cell lines and thus these miRNAs may
contribute to the function of these oncogenes/tumor
suppressors. Finally, certain miRNAs themselves are
located in genomic regions, which frequently show
genetic aberrations, implying that these miRNAs them-
selves may have a potential driver role or contribute to
known drivers in these genomic regions. Our current
findings call for further validation of these signatures in
clinical specimens. Importantly, our study provides a
unique molecular miRNA portrait of human breast can-
cer cell lines, which can be exploited for functional stu-
dies of clinically important miRNAs.
Additional material
Additional file 1: an Excel file of Tables S1 to S20 containing lists of
differentially expressed miRNAs associated with breast cancer
molecular subtypes and recurrent genetic aberrations.
Additional file 2: Figure S1 showing differential expression of
miRNAs between ER-positive and ER-negative human breast cancer
cell lines. Cell lines have been grouped into ER-positive and ER-negative
groups based on their mRNA expression levels measured by microarray.
Yellow and blue, high and low overall similarity of samples in miRNA
expression, respectively. Figure S2 showing differential expression of
miRNAs between cell lines mutant and wild-type for BRCA1 and PIK3CA/
PTEN genes. (A) miRNA differential expression associated with PIK3CA/
PTEN mutations in all, the luminal-group, and the ER-negative/basal-
group of breast cancer cell lines. (B) miRNA differential expression
associated with BRCA1 mutation. Yellow and blue, high and low overall
similarity of samples in miRNA expression, respectively. Figure S3
showing differential expression miRNAs between cell lines mutant and
wild-type for the TP53 gene. Cell lines with TP53 heterozygous mutation
(OCUB-F) and with undetermined TP53 mutation status (HCC202,
HCC1395, HCC1500) were excluded from the analysis. Yellow and blue,
high and low overall similarity of samples in miRNA expression,
respectively. Figure S4 showing comparison of median genomic
distances of ER binding sites and significantly and nonsignificantly
differentially associated miRNAs with ER status of the cell lines. The
Mann-Whitney test was used to compare the median genomic distances
of ER binding sites and miRNAs.
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